U.S. Lobbying and Political Contributions Policy

Sarepta Therapeutics, Inc. ("we", or the "Company") is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. To advance this mission, we seek to transform how the world approaches the treatment of serious and life-threatening diseases, including by engaging a diverse group of external stakeholders. Government decisions, in particular, have a significant impact on our efforts, industry, and patients. Therefore, it is essential for us to actively and responsibly engage government officials and policymakers at the federal, state, and local levels to help advance informed regulations, laws, and other public policy developments that create an environment which supports patients, propels science, and encourages innovation. We believe that Sarepta's integrity and reputation depend on the honesty and fairness brought to the job by each person associated with us, as outlined in our Code of Business Conduct and Ethics. We maintain high standards of honest and ethical business conduct and follow all applicable federal, state, and local laws related to our political activities in the United States.

Oversight

Our Company's Board of Directors has adopted this U.S. Lobbying and Political Contributions Policy (the "Policy") and delegated oversight of the Policy to its Nominating and Corporate Governance Committee. The Policy and related activities pursuant to the Policy are annually reviewed by senior management with the Nominating and Corporate Governance Committee of the Board. The adoption of this Policy further demonstrates the Company's commitment to transparency and accountability.

Lobbying

When we determine it is in the best interests of the Company, we work with all levels of government to provide information and perspective to support our goals and help ensure sound policies are developed through lobbying. We comply with all applicable federal, state, and local lobbying laws and rules. Under the Lobbying Disclosure Act, we file quarterly reports with the U.S. Congress disclosing our federal lobbying activities, including lobbying expenditures. These disclosures can be found on the U.S. Senate Office of Public Records website and the U.S. House of Representatives Office of the Clerk website.

Political Contributions

Federal candidates

Federal law prohibits corporations from making direct political contributions to federal candidates, parties, and committees and Sarepta complies fully with this requirement. ***State and Local Candidates***

The Company periodically contributes to state and local candidates, where permitted by applicable law, when we believe candidates could facilitate the advancement of our business objectives. These contributions are bipartisan and support both policies and candidates that align with our mission.

Sarepta Federal Political Action Committee

Federal law permits a corporation to establish a political action committee (PAC) that can make contributions to federal candidates. The Sarepta Therapeutics, Inc. Political Action Committee (the "Sarepta PAC") is designed for this purpose; it is funded solely by voluntary contributions from eligible Sarepta employees and none of its funds come from Sarepta corporate monies. Sarepta PAC's receipts and disbursements are regularly reported to the U.S. Federal Election Commission (FEC) and available for viewing on the FEC's website.

Sarepta PAC operations, including decisions regarding potential recipients of Sarepta PAC contributions, are overseen by a PAC Board. PAC contributions are bipartisan and based on the ability of a candidate to advance the mission and interests of Sarepta. A contribution from Sarepta PAC does not suggest that

Sarepta agrees with the candidate on every issue.

Trade associations

We believe in collaborating with our community and industry. Sarepta is a member of trade associations and industry groups that align with our mission and business objectives. Our government affairs and policy team regularly reviews our memberships to ensure ongoing alignment with our mission and corporate goals. While we are committed to participating in industry and trade group discussions, Sarepta's participation or membership does not imply that we agree with every position they may take on an issue.

These organizations may use membership dues to engage in lobbying activities. We do not direct, nor have discretion over, how these funds are used.

Under this Policy, we will annually disclose in Annex A a list of trade associations to which we pay annually at least $50,000 in dues or other payments and the portion of those payments that were used for activities that are not deductible under Chapter 162(e) of the Internal Revenue Code. The Company will retain an archive of annexes to this Policy, which the Company makes available to stockholders upon request.

Other organizations

We may provide financial support from time to time to other political organizations, including 527 organizations and nonprofit organizations established under Section 501(c)(3), 501(c)(4) and 501(c)(6) of the Internal Revenue Code that align with our goals and mission.

Questions

Questions about our lobbying and political contributions policy should be directed to Sarepta's Executive Vice President, Chief Global Policy & Advocacy Officer.

ANNEX

Trade Associations

Organization		**2025 Non-Deductible Portion of Payments ($)**
Biotechnology Innovation Organization		$95,787.41
Rare Disease Company Coalition		$27,562.50

501(c)(4) Organizations

Organization		**2025 Non-Deductible Portion of Payments ($)**
Alliance for Regenerative Medicine		$14,400
Institute for Gene Therapies		$60,000

Corporate Contributions to Political Organizations

Recipient		**2025 Amount ($)**
Democratic Governors Association		$60,000
Democratic Legislative Campaign Committee		$25,000
Democratic Lieutenant Governors Association		$40,000
GOPAC, INC		$35,000
Republican Governors Association		$75,000
Republican Legislative Campaign Committee		$50,000
Republican Lieutenant Governors Association		$15,000

Adopted April 21, 2026